Related Experiment Video

Updated: Dec 12, 2025

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.2K

Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals

Nicolas Penel1,2, Thomas Ryckewaert1, Diane Pannier1

  • 1Medical Oncology Department, Oscar Lambret Center, Lille, France.

Cancer
|August 9, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.5K
Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

3.4K

Related Experiment Videos

Last Updated: Dec 12, 2025

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.2K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.5K
Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
08:56

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

3.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K

Articles linked to this work by shared authors, journal, and citation graph.

[Tenosyovial giant cell tumor (TGCT): From the physiopathology to the emergence of new targeted therapies].

Bulletin du cancer·2026

Molecular profiling and access to treatment for rare cancers in Europe.

Nature communications·2026

Deni Study: Real-World Data on the Use of Nirogacestat in Patients With Desmoid Tumors in the French Sarcoma Group.

International journal of cancer·2026

MiT fusions, TSC1-TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa.

Nature communications·2026

Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study.

British journal of cancer·2026

Outcome of 1773 superficial non-dermatofibrosarcoma sarcomas A French Sarcoma Group study (FSG) from the NETSARC database.

European journal of cancer (Oxford, England : 1990)·2025

Outcomes of adult patients with Li-Fraumeni syndrome and myeloid neoplasms.

Cancer·2026

Impact of post-chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children's Oncology Group AREN0532, AREN0533, and AREN03B2 studies.

Cancer·2026

Long-term patient-reported outcomes and toxicity following salvage radiotherapy for biochemical recurrence after radical prostatectomy.

Cancer·2026

Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real-world study.

Cancer·2026

IMMU-NO versus yes: Applicability of immune checkpoint inhibitors in gynecologic cancers.

Cancer·2026

Effect of demographic characteristics on the outcome of prostate cancer salvage radiotherapy: Analysis from a randomized controlled trial.

Cancer·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us